Comparative study of Yashida and Norvasc in chronic renal insufficiency with hypertension

OBJECTIVE To evaluate the antihypertensive effect and safety of Yashida and Norvasc in the treatment of chronic renal insufficiency patients with hypertension.METHODS Sixty-three patients with chronic renal insufficiency(Scr:265～442μmol·L-1,seated DBP 90～105mmHg and seated SBP≤170mmHg) were enrolled in this study.Patients were randomly assigned to receive Yashida 5mg or Novasc 5mg once daily for 4 weeks.Doses were titrating to 10mg·d-1 for another 4 weeks in patients having seated DBP≥80mmHg or SBP≥130mmHg at the end of 4 weeks.Blood pressure,heart rate,laboratory examinations were performed at baseline and the end of the tria1,and side effects were assessed pre and post Yashida or Novasc treatment.RESULTS Yashida group and Novasc group finished a 8 week clinical tria1.At the end of 4,8 weeks,seated SBP and DBP were significantly lowered compared with those at baseline(P0.01).There was no significant difference in the reduction of seated DBP or SBP between the two groups at the end of 4,8 weeks(P0.05).At the end of 8 weeks,the response rate was 88% in Yashida group and 90% in Novasc group.If the target value of blood pressure is below 130/80mmHg,the response rate was 37.5% in Yashida group and 32.2% in Novasc group.At the end of 8 weeks,no difference was found in laboratory findings compared with those at baseline in the two groups(P0.05).Side effects were comparable during the period of treatment.CONCLUSION Yashida 5mg or 10mg daily is as effective and safe as Novasc in chronic renal insufficiency patients with hypertension.